Drugs / GVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00426205 | Jun 2004 → Sep 2007 | acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome with excess blasts | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX | “The vaccine used in this trial, called GVAX, will be made from the participants own leukemia cells, and will be given between 1-4 months after transplant.” NCT00426205 ↗ |
| Modality | Vaccine | “The vaccine used in this trial, called GVAX” NCT00426205 ↗ |
| Route | Subcutaneous | “The vaccine will be administered subcutaneously and intradermally on the arm, leg, or abdomen 6 times.” NCT00426205 ↗ |